Series C funding led by Draper Esprit. Brings total funding for Endomag to over $22 million USD (£17M GBP). Investment will be used to expand commercial activity.
7/17/18: “The expedited growth of connected medical devices poses exceptional challenges for hospital network security. Connected devices have become an integral part of hospitals’ IT networks, yet they are not monitored and remain unprotected. Recent massive cyber-attacks such as OrangeWorm, NotPetya and WannaCry illustrate the challenges and high-risk exposure for hospitals,” said Amir Magner, CEO at CyberMDX.
Cagent Vascular Raises $11.87M to Fund the Growth and Expansion of the Serranator Family of Percutaneous Transluminal Angioplasty Serration Balloon Catheters
7/12/18: “The breadth and diversity of the investor base reflects an understanding of the value proposition that this technology delivers,” stated CEO, Carol A. Burns.
Shifamed Announces $15.5M Series A Financing Supira Medical, Newly Formed Portfolio Company, Focuses on Next Generation PVAD
6/13/18: Supira Medical is focused on the development of a next generation percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. The team is led by Jean Orth, appointed to CEO of Supira in December 2017
Zebra Medical Vision Raises $30M, Unveils the Broadest, Automated AI Based Radiology Chest X-Ray Reader to Date
“I am pleased to partner with Zebra Medical Visions’ distinguished panel of investors,” added Morris Kahn, founder and owner of Aurum Ventures. “I am a big believer in AI based healthcare solutions and Zebra Medical Vision's technologies will play a major role in improving the capacity and quality of treatment for patients all over the world.”
AVITA Medical Announces Institutional Placement of A$16 Million to Support U.S. Commercialization of the RECELL Device
“We appreciate the support of our shareholder group and the investors in this institutional placement as we proceed toward a transformative series of events for AVITA, including the U.S. market launch of the RECELL Device,“ said Dr. Michael Perry, Chief Executive Officer. “Proceeds from this placement will ensure that we are positioned to take full advantage of the expected upcoming PMA approval of the RECELL Device in the U.S., including establishment of our marketing and sales team, scale-up of manufacturing capabilities and expansion of clinical development. The extensive series of clinical data presented at the recent ABA and ISPOR conferences strongly supports the value of RECELL in the treatment of severe burns, and we have an exceptional commercial opportunity resulting from the unique combination of improved patient outcomes and substantial health economic benefits.”
Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts
6/5/18: Each of the company’s current investors participated in the financing, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures, and Schrödinger. Bruce Booth, Partner of Atlas Venture, Board Chair and co-founder of Nimbus noted, “this round of investment reflects the existing syndicate’s strong and enthusiastic support for Nimbus’ proven management team and exciting new programs.”
Ancora Heart Announces $17.8 Million Financing for First-of-Its-Kind Therapy for Systolic Heart Failure
5/30/18: “Effectively treating heart failure and FMR is incredibly challenging today, and there are enormous unmet needs for these patients. This funding represents an important milestone that will advance the AccuCinch system as an alternative option that addresses the shortcomings of current heart failure and FMR treatments,” said Jeff Closs, president and CEO of Ancora Heart.